Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Nephros (NEPH) EBITDA Margin (2016 - 2025)

Nephros has reported EBITDA Margin over the past 16 years, most recently at 0.38% for Q4 2025.

  • Quarterly results put EBITDA Margin at 0.38% for Q4 2025, down 781.0% from a year ago — trailing twelve months through Dec 2025 was 6.1% (up 584.0% YoY), and the annual figure for FY2025 was 6.1%, up 606.0%.
  • EBITDA Margin for Q4 2025 was 0.38% at Nephros, down from 6.59% in the prior quarter.
  • Over the last five years, EBITDA Margin for NEPH hit a ceiling of 11.61% in Q1 2025 and a floor of 134.12% in Q3 2022.
  • Median EBITDA Margin over the past 5 years was 10.98% (2024), compared with a mean of 24.45%.
  • Biggest five-year swings in EBITDA Margin: tumbled -8889bps in 2022 and later skyrocketed 12926bps in 2023.
  • Nephros' EBITDA Margin stood at 40.73% in 2021, then decreased by -9bps to 44.37% in 2022, then surged by 55bps to 20.1% in 2023, then soared by 141bps to 8.19% in 2024, then tumbled by -95bps to 0.38% in 2025.
  • The last three reported values for EBITDA Margin were 0.38% (Q4 2025), 6.59% (Q3 2025), and 5.61% (Q2 2025) per Business Quant data.